Real-time SEC alerts Start Free →
Profitelligence
Abbott Laboratories
ABT HIGH Impact

Abbott Laboratories

Abbott Laboratories Appoints New Board Member and Adopts New Incentive Stock Program

| 8-K |Healthcare

Summary

On April 24, 2026, Abbott Laboratories appointed Kevin Conroy to its Board of Directors and adopted the Abbott Laboratories 2026 Incentive Stock Program, replacing the 2017 Program. The new program allows Abbott to grant various equity-based awards to its directors and employees. Additionally, Abbott's Board amended the bylaws to increase the board size to thirteen members. Shareholders also approved the appointment of Ernst & Young LLP as Abbott's auditors, the compensation of named executive officers, and the new incentive stock program and employee stock purchase plan for non-U.S. employees.

Profitelligence Profitelligence Alerts

Get alerts for ABT

Be first to know when Abbott Laboratories files with the SEC.

Set Up Alerts →

Filing Categories

Board Member Appointed New Major Contract Bylaw Amendment General Statement Shareholder Rights Plan (Poison Pill)

Advertisement

About Abbott Laboratories

Abbott Laboratories, a globally renowned company, specializes in the development and production of healthcare and medical products. Founded in 1888 and headquartered in Abbott Park, Illinois, Abbott is a pivotal entity in the healthcare sector. The company provides essential products spanning diagnostics, medical devices, nutritional products, and branded generic pharmaceuticals. Notably, Abbott's extensive diagnostic solutions include immunoassays and molecular diagnostics, crucial for medical testing and healthcare management. Its medical devices division produces cardiovascular and neuromodulation products, enhancing patient care across diverse medical practices. Abbott’s nutritional segment, featuring well-known brands like Similac and Ensure, supports health and wellness across various demographics. Serving markets globally, Abbott Laboratories plays a critical role in advancing healthcare infrastructure and delivering innovative solutions that address evolving health challenges worldwide. As a significant player in the life sciences field, Abbott's contributions significantly influence patient outcomes and healthcare delivery systems.

Exchange: NYSE Industry: Medical Devices Company Website →

Official SEC Documents

ABT
ABT Research
8Ks, insider trades, financials, technicals
SEC Alert Manager
Get alerts within 60 seconds of new filings

Advertisement